These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 19620191)

  • 1. Expanded newborn screening: outcome in screened and unscreened patients at age 6 years.
    Wilcken B; Haas M; Joy P; Wiley V; Bowling F; Carpenter K; Christodoulou J; Cowley D; Ellaway C; Fletcher J; Kirk EP; Lewis B; McGill J; Peters H; Pitt J; Ranieri E; Yaplito-Lee J; Boneh A
    Pediatrics; 2009 Aug; 124(2):e241-8. PubMed ID: 19620191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropsychological functioning in children with medium chain acyl coenzyme a dehydrogenase deficiency (MCADD): the impact of early diagnosis and screening on outcome.
    Joy P; Black C; Rocca A; Haas M; Wilcken B
    Child Neuropsychol; 2009 Jan; 15(1):8-20. PubMed ID: 18608229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening newborns for inborn errors of metabolism by tandem mass spectrometry.
    Wilcken B; Wiley V; Hammond J; Carpenter K
    N Engl J Med; 2003 Jun; 348(23):2304-12. PubMed ID: 12788994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanded newborn screening by tandem mass spectrometry: the Massachusetts and New England experience.
    Marsden D
    Southeast Asian J Trop Med Public Health; 2003; 34 Suppl 3():111-4. PubMed ID: 15906712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study.
    Wilcken B; Haas M; Joy P; Wiley V; Chaplin M; Black C; Fletcher J; McGill J; Boneh A
    Lancet; 2007 Jan; 369(9555):37-42. PubMed ID: 17208640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Screening of newborns for inborn errors of metabolism by tandem mass spectrometry].
    Simonsen H
    Ugeskr Laeger; 2002 Nov; 164(48):5607-12. PubMed ID: 12523003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The failure to diagnose inborn errors of metabolism in New Zealand: the case for expanded newborn screening.
    Wilson C; Kerruish NJ; Wilcken B; Wiltshire E; Webster D
    N Z Med J; 2007 Sep; 120(1262):U2727. PubMed ID: 17891215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzymatic diagnosis of medium-chain acyl-CoA dehydrogenase deficiency by detecting 2-octenoyl-CoA production using high-performance liquid chromatography: a practical confirmatory test for tandem mass spectrometry newborn screening in Japan.
    Tajima G; Sakura N; Yofune H; Nishimura Y; Ono H; Hasegawa Y; Hata I; Kimura M; Yamaguchi S; Shigematsu Y; Kobayashi M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Sep; 823(2):122-30. PubMed ID: 16046200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of newborns and high-risk group of children for inborn metabolic disorders using tandem mass spectrometry in South Korea: a three-year report.
    Yoon HR; Lee KR; Kang S; Lee DH; Yoo HW; Min WK; Cho DH; Shin SM; Kim J; Song J; Yoon HJ; Seo S; Hahn SH
    Clin Chim Acta; 2005 Apr; 354(1-2):167-80. PubMed ID: 15748614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of tandem mass spectrometry newborn screening in Australia.
    Norman R; Haas M; Chaplin M; Joy P; Wilcken B
    Pediatrics; 2009 Feb; 123(2):451-7. PubMed ID: 19171609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newborn screening for medium chain acyl CoA dehydrogenase deficiency.
    Leonard JV; Dezateux C
    Arch Dis Child; 2009 Mar; 94(3):235-8. PubMed ID: 18838415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Data mining methods for classification of Medium-Chain Acyl-CoA dehydrogenase deficiency (MCADD) using non-derivatized tandem MS neonatal screening data.
    Van den Bulcke T; Vanden Broucke P; Van Hoof V; Wouters K; Vanden Broucke S; Smits G; Smits E; Proesmans S; Van Genechten T; Eyskens F
    J Biomed Inform; 2011 Apr; 44(2):319-25. PubMed ID: 21167313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy.
    Sims EJ; Clark A; McCormick J; Mehta G; Connett G; Mehta A;
    Pediatrics; 2007 Jan; 119(1):19-28. PubMed ID: 17200267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced incidence of severe metabolic crisis or death in children with medium chain acyl-CoA dehydrogenase deficiency homozygous for c.985A>G identified by neonatal screening.
    Nennstiel-Ratzel U; Arenz S; Maier EM; Knerr I; Baumkötter J; Röschinger W; Liebl B; Hadorn HB; Roscher AA; von Kries R
    Mol Genet Metab; 2005 Jun; 85(2):157-9. PubMed ID: 15896661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel.
    Insinga RP; Laessig RH; Hoffman GL
    J Pediatr; 2002 Oct; 141(4):524-31. PubMed ID: 12378192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry.
    Tran K; Banerjee S; Li H; Noorani HZ; Mensinkai S; Dooley K
    Clin Biochem; 2007 Feb; 40(3-4):235-41. PubMed ID: 17222812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expanded newborn screening in the Region of Murcia, Spain. Three-years experience].
    Juan-Fita MJ; Egea-Mellado JM; González-Gallego I; Moya-Quiles MR; Fernández-Sánchez A
    Med Clin (Barc); 2012 Dec; 139(13):566-71. PubMed ID: 22137990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. State newborn screening in the tandem mass spectrometry era: more tests, more false-positive results.
    Tarini BA; Christakis DA; Welch HG
    Pediatrics; 2006 Aug; 118(2):448-56. PubMed ID: 16882794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland--experience and development of a routine program for expanded newborn screening.
    Lund AM; Hougaard DM; Simonsen H; Andresen BS; Christensen M; Dunø M; Skogstrand K; Olsen RK; Jensen UG; Cohen A; Larsen N; Saugmann-Jensen P; Gregersen N; Brandt NJ; Christensen E; Skovby F; Nørgaard-Pedersen B
    Mol Genet Metab; 2012 Nov; 107(3):281-93. PubMed ID: 22795865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare use and costs of medium-chain acyl-CoA dehydrogenase deficiency in Australia: screening versus no screening.
    Haas M; Chaplin M; Joy P; Wiley V; Black C; Wilcken B
    J Pediatr; 2007 Aug; 151(2):121-6, 126.e1. PubMed ID: 17643760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.